research Bexxar, iodine I 131 tositumomab, Effective in Long Term Follow-up of Non-Hodgkin's Lymphoma
Bexxar is highly effective as a first treatment for non-Hodgkin's lymphoma, with most patients alive and many in remission after eight years.
Search
for
Sort by
Research
90-120 / 1000+ results 
research P64 Efficacy of baricitinib in patients with different degrees of severe alopecia areata: 52-week results from BRAVE-AA1 and BRAVE-AA2
Baricitinib was effective in treating severe and very severe alopecia areata after 52 weeks.
research USE OF UPADACITINIB IN 2 CASES OF REFRACTORY SYSTEMIC LUPUS ERYTHEMATOSUS
Upadacitinib may help treat difficult cases of systemic lupus erythematosus.
research Efficacy and Tolerability of Brevilin-A, a Natural JAK Inhibitor, in Pediatric Alopecia Areata: A Case Series
Brevilin-A is a safe and effective treatment for mild to moderate alopecia areata in children.
research Ruxolitinib: A novel molecule in the management of dermatological disorders
Ruxolitinib cream effectively treats skin conditions like atopic dermatitis and vitiligo with minimal side effects.
research P79: Efficacy of baricitinib in adults with alopecia areata: patients’ perspectives on hair regrowth from two phase III randomized controlled trials (BRAVE‐AA1 and BRAVE‐AA2)
Baricitinib was effective in treating hair loss in adults with alopecia areata according to patient feedback.
research Anlotinib or Bevacizumab Combined with Taxane/Capecitabine for the Second-Line or Subsequent Treatment of HER-2 Negative Metastatic Breast Cancer: A Retrospective Cohort Study
Anlotinib combined with taxane/capecitabine is more effective than bevacizumab for treating HER-2 negative metastatic breast cancer.
research Integrated Safety Analysis of Ritlecitinib in Adolescent Patients with Alopecia Areata from the Randomized, Placebo-Controlled ALLEGRO Phase 2b/3 and Ongoing Open-Label Phase 3 ALLEGRO-LT Studies
research Update: baricitinib for alopecia areata
Baricitinib is effective and safe for treating severe alopecia areata with ongoing use.
research Effective treatment of refractory alopecia areata in pediatric patients with oral abrocitinib
A new drug, abrocitinib, helped a child with severe hair loss regrow hair.
research Safety of Baricitinib in Adults with Severe Alopecia Areata from Two Phase III Trials Over a Median of 2.3 Years and Up to 4 Years of Treatment
Baricitinib is generally safe for long-term use in treating severe alopecia areata.
research Comprehensive Safety Exposure‐Response Analysis to Support Ritlecitinib Dose Selection
A 50 mg non-loading dose of ritlecitinib is safe for adults and adolescents.
research 1108 Comparison of ruxolitinib and a collagen-targeted PTH-based hair cycle stimulant on hair follicle counts and hair growth in the C3H/HeJ engrafted mouse model of alopecia areata
A PTH-based treatment improved hair regrowth better than ruxolitinib in a mouse model of hair loss.
research Long‐term efficacy and safety of baricitinib in patients with severe alopecia areata: 104‐week results from BRAVE‐AA1 and BRAVE‐AA2
Baricitinib is effective and safe for long-term use in severe alopecia areata, improving hair regrowth and quality of life with few side effects.
research Alisertib is active as single agent in recurrent atypical teratoid rhabdoid tumors in 4 children
Alisertib was found to be an effective and tolerable treatment for children with recurrent brain tumors.
research Toxic Side Effects of Targeted Therapies and Immunotherapies Affecting the Skin, Oral Mucosa, Hair, and Nails
Cancer treatments targeting specific cells and the immune system can cause skin, mouth, hair, and nail problems, affecting patients' quality of life and treatment adherence.
research Identifying the Target Cells and Mechanisms of Merkel Cell Polyomavirus Infection
Human dermal fibroblasts are the main cells targeted by a virus that can cause a deadly skin cancer, and a certain inhibitor can effectively block this infection.
research Alopecia in patients treated with molecularly targeted anticancer therapies
Targeted cancer therapies have a significant but lower risk of causing hair loss compared to chemotherapy.
research Investigation of Suicidality and Psychological Adverse Events in Patients Treated With Finasteride
Finasteride may cause suicidal thoughts and mental side effects, especially in young people with hair loss.
research TCL1 transgenic mouse model as a tool for the study of therapeutic targets and microenvironment in human B-cell chronic lymphocytic leukemia
The TCL1 transgenic mouse model is useful for understanding human B-cell leukemia and testing new treatments.
research New small molecules in dermatology: for the autoimmunity, inflammation and beyond
New small molecule drugs show promise in treating complex skin diseases but need more safety research.
research Cutaneous toxicities of new targeted cancer therapies: must know for diagnosis, management, and patient-proxy empowerment
New targeted cancer drugs can cause skin side effects, and managing them requires patient education and timely care.
research Dermatologic Adverse Events from Cancer Treatments
Cancer treatments can cause skin-related side effects that may affect patient quality of life and require changes in treatment.
research NF-κB in biology and targeted therapy: new insights and translational implications
NF-κB signaling is crucial in many diseases and can be targeted for new treatments.
research Analysis of chemotherapy-induced peripheral neuropathy using the Japanese Adverse Drug Event Report database
Certain cancer drugs are strongly linked to nerve damage, requiring close monitoring and early treatment.
research Development and Evaluation of a Niosome-Integrated Microneedle System for Targeted Follicular Delivery of Ketoconazole in Alopecia Therapy
The new microneedle system improves hair growth in alopecia treatment.
research Evidence Synthesis Gone Awry: The Perils of Aggregating Ineffective or Unsafe Doses in Alopecia Areata Reviews
Including ineffective or unsafe doses in reviews can lead to misleading conclusions about alopecia areata treatments.
research Integrated Safety Analysis of Ritlecitinib, an Oral JAK3/TEC Family Kinase Inhibitor, for the Treatment of Alopecia Areata from the ALLEGRO Clinical Trial Program
Ritlecitinib is safe and well-tolerated for treating alopecia areata in patients aged 12 and older.
research FORMULATION AND EVALUATION OF MINOXIDIL GEL IN COMBINATION WITH ALOE VERA FOR TOPICAL APPLICATION FOR THE TREATMENT OF ALOPECIA
The gel combining minoxidil and Aloe vera could be an effective, non-irritating treatment for hair loss.
research Poster Abstracts
The model and estimator can predict drug exposure in kidney transplant patients well.